Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Cash from Investing Activities: 2022-2025

Historic Cash from Investing Activities for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to -$27,000.

  • Phathom Pharmaceuticals' Cash from Investing Activities rose 38.64% to -$27,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$147,000, marking a year-over-year increase of 75.70%. This contributed to the annual value of -$135,000 for FY2024, which is 91.74% up from last year.
  • Phathom Pharmaceuticals' Cash from Investing Activities amounted to -$27,000 in Q3 2025, which was up 72.16% from -$97,000 recorded in Q2 2025.
  • Phathom Pharmaceuticals' 5-year Cash from Investing Activities high stood at -$5,000 for Q4 2024, and its period low was -$939,000 during Q3 2023.
  • Its 3-year average for Cash from Investing Activities is -$173,727, with a median of -$44,000 in 2024.
  • Examining YoY changes over the last 5 years, Phathom Pharmaceuticals' Cash from Investing Activities showed a top increase of 98.95% in 2024 and a maximum decrease of 666.67% in 2024.
  • Phathom Pharmaceuticals' Cash from Investing Activities (Quarterly) stood at -$412,000 in 2022, then declined by 15.29% to -$475,000 in 2023, then spiked by 98.95% to -$5,000 in 2024, then soared by 38.64% to -$27,000 in 2025.
  • Its Cash from Investing Activities was -$27,000 in Q3 2025, compared to -$97,000 in Q2 2025 and -$18,000 in Q1 2025.